Jupiter Endovascular closes Series B above $40M a month after Vertex clearance

MedDevice Startups Staff · Oct 7 · 2 min read · Via Company release (Business Wire)

Jupiter Endovascular closed a Series B that beat its $40 million target, the Menlo Park, California company said on October 7, 2025. Sonder Capital led. Senvest Management, LB Investment and an unnamed strategic corporate investor joined.

The round lands a month after FDA cleared the Vertex catheter under K252027 on September 12. The submission was received June 30, so the review took 74 days. Vertex uses Jupiter's transforming fixation technology. The catheter tracks over a wire in a relaxed state, then pressurizes with saline to lock in place. It relaxes again to reposition or withdraw. FDA granted an IDE for the pulmonary embolism program in August 2024.

Proceeds fund the SPIRARE II trial in acute intermediate-risk pulmonary embolism, plus launch preparation. The trial plans up to 145 patients at up to 25 sites in the U.S. and Europe. A 510(k) on the catheter while the PE indication runs through an IDE is a familiar two-track play. The cleared product gets the device into physicians' hands before the trial reads out.

Questions & Answers

How much did Jupiter Endovascular raise in its Series B?

Jupiter Endovascular closed an oversubscribed Series B of more than $40 million on October 7, 2025. Sonder Capital led, joined by Senvest Management, LB Investment and an unnamed strategic corporate investor.

What did FDA clear under K252027?

K252027 is the 510(k) for Jupiter Endovascular's Vertex catheter, cleared September 12, 2025. FDA received the submission on June 30, so the review took 74 days.

What is the SPIRARE II trial?

SPIRARE II is Jupiter Endovascular's IDE trial of the Vertex system in acute intermediate-risk pulmonary embolism. It plans up to 145 patients at up to 25 sites in the U.S. and Europe.

← Back to Fundraising